venBio Partners LLC
CIK: 0001776382Latest portfolio: $216.3M · Q4 2025
Holdings
6
Total Value
$216.3M
New Positions
0
Closed Positions
0
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | PHVSPHARVARIS N V | 4,639,304 | $128.7M | 59.53% | — | |
| 2 | ALMSALUMIS INC | 4,619,803 | $45.1M | 20.85% | — | |
| 3 | HRMYHARMONY BIOSCIENCES HLDGS IN | 489,194 | $18.3M | 8.46% | — | |
| 4 | ALXOALX ONCOLOGY HLDGS INC | 9,699,925 | $11.0M | 5.07% | — | |
| 5 | LYELLYELL IMMUNOPHARMA INC | 337,697 | $10.4M | 4.81% | -135,782 | |
| 6 | ARTVARTIVA BIOTHERAPEUTICS INC | 648,507 | $2.8M | 1.29% | -500,468 |
Sector Breakdown
Healthcare100.0% ($128740450891830509568.0T)
Filing History
Fund Information
venBio Partners LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $216.3M across 6 holdings. The largest position is PHARVARIS N V (PHVS), representing 59.5% of the portfolio. Compared to the previous quarter, the fund opened 0 new positions and closed 0 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.